Arteriovenous Fistula, Brain Arteriovenous Malformation
Conditions
Keywords
brain arteriovenous malformation, arteriovenous fistula, LIQUID EMBOLIC AGENT
Brief summary
This study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion and exclusion criteria specified in this trial protocol, approximately 116 subjects with brain arteriovenous malformation will be enrolled for interventional embolization treatment. The subjects will undergo follow-up before the surgery, after device implantation, at discharge, 1 month (± 7 days), 6 months (± 30 days), and 12 months (± 60 days) after the first embolization. When necessary, unscheduled follow-up will be conducted to record various indicators for evaluating the safety and effectiveness of liquid embolic agents in the treatment of brain arteriovenous malformations.
Interventions
DEVICEliquid embolic agent
liquid embolic agent
Sponsors
MicroPort NeuroTech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Masking Description
Intervention model description
Model Description
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 and ≤ 80 years at the time of signing the informed consent * Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA * The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ \ Ⅳ * Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form * Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator
Exclusion criteria
* Multiple brain arteriovenous malformations * Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period * Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years * Brain arteriovenous malformation with bleeding within 1 week * Brain arteriovenous malformation with an expected number of embolizations ≥ 4 * Brain arteriovenous malformation scheduled for surgical resection after embolization * mRS score ≥ 3 * Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc * Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.) within 30 days prior to signing the informed consent form, or those scheduled for such procedures within 60 days after signing the informed consent form * Contraindications for liquid embolic agent treatment, including but not limited to: contraindications for DSA, severe allergy or intolerance to contrast agents, severe allergy or intolerance to antiplatelet or anticoagulant medications required for treatment, or severe allergy to tantalum metal * Pregnant or lactating women * Subjects participating in other drug or device studies that have not reached their endpoints or who have just withdrawn from the group for less than one month
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of effective embolization of target brain arteriovenous malformation | Perioperative | Effective embolization refers to a reduction of ≥ 50% after the last embolization of the target brain arteriovenous malformation compared with that before the first embolization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of favorable clinical outcomes during the 1 year follow-up period | 1 year after procedure | Favorable clinical outcome refers to a mRS score of ≥ 0 and ≤ 2 |
| Incidence of symptomatic stroke or death within one month after procedure | 1 month after procedure | — |
| Incidence of symptomatic intracranial hemorrhage related to procedure within 1 month after procedure | 1 month after procedure | — |
| Incidence of symptomatic ischemic stroke related to procedure within 1 month after procedure | 1 month after procedure | — |
| Incidence of device-related serious adverse events during the 1 year follow-up period | 1 year after procedure | — |
Countries
China
Contacts
Primary ContactLiu Shugen
Outcome results
None listed